Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease

Potential therapeutic significance

Katharina Clodi, Zahra Asgari, Mamoun Younes, J. Lynn Palmer, Fernando Cabanillas, Antonino Carbone, Michael Andreeff, Anas Younes

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

BACKGROUND. The malignant Hodgkin and Reed-Sternberg (H/RS) cells of Hodgkin disease (HD) express CD30 and CD40 receptors that can activate nuclear factor kappa B and transduce survival signals. The authors have reported previously that the B lymphocytes of HD express CD30 ligand (CD30L, CD153). Furthermore, they and others have reported previously that the CD40L survival pathway is augmented in patients with B-cell malignancies, as CD40L was constitutively expressed by the malignant B cells and infiltrating T cells, and sera from those patients contained elevated levels of soluble CD40L. In this study, the authors investigated the hypothesis that the survival of H/RS cells was similarly promoted by an augmented CD40L signals in HD patients. METHODS. The expression of CD40L on lymphocyte subsets of patients with classic HD was determined by two-color fluorescent-activated cell sorter analysis. Serum soluble CD40L levels were determined by enzyme linked immunosorbent assay. RESULTS. CD40L was constitutively expressed on both the T and B cells of HD patients but was more prominently expressed on the B lymphocytes. Soluble CD40L was detected in the serum of 17 of 37 patients (45%) and was higher than 1 ng/mL in 4 patients (10%). Both interleukin (IL)-4 and IL-10, which are known to be secreted by H/RS cells and surrounding T cells, up-regulated CD40L expression on normal B cells. CONCLUSIONS. Thus, the expression of CD40L and CD30L on the B cells of HD patients suggests that B lymphocytes may play a role in the regulation of H/RS cell growth in vivo. Depriving H/RS cells from CD30L and CD40L survival signals by eliminating B cells from HD lesions may be of therapeutic value.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalCancer
Volume94
Issue number1
DOIs
Publication statusPublished - Jan 1 2002

Fingerprint

CD40 Ligand
Hodgkin Disease
B-Lymphocytes
T-Lymphocytes
Reed-Sternberg Cells
Therapeutics
CD30 Ligand
Serum
Survival
NF-kappa B
Lymphocyte Subsets
Interleukin-4
Interleukin-10
Color
Enzyme-Linked Immunosorbent Assay

Keywords

  • B lymphocytes
  • CD154
  • CD40
  • Reed-Sternberg cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clodi, K., Asgari, Z., Younes, M., Palmer, J. L., Cabanillas, F., Carbone, A., ... Younes, A. (2002). Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: Potential therapeutic significance. Cancer, 94(1), 1-5. https://doi.org/10.1002/cncr.10164

Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease : Potential therapeutic significance. / Clodi, Katharina; Asgari, Zahra; Younes, Mamoun; Palmer, J. Lynn; Cabanillas, Fernando; Carbone, Antonino; Andreeff, Michael; Younes, Anas.

In: Cancer, Vol. 94, No. 1, 01.01.2002, p. 1-5.

Research output: Contribution to journalArticle

Clodi, K, Asgari, Z, Younes, M, Palmer, JL, Cabanillas, F, Carbone, A, Andreeff, M & Younes, A 2002, 'Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: Potential therapeutic significance', Cancer, vol. 94, no. 1, pp. 1-5. https://doi.org/10.1002/cncr.10164
Clodi, Katharina ; Asgari, Zahra ; Younes, Mamoun ; Palmer, J. Lynn ; Cabanillas, Fernando ; Carbone, Antonino ; Andreeff, Michael ; Younes, Anas. / Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease : Potential therapeutic significance. In: Cancer. 2002 ; Vol. 94, No. 1. pp. 1-5.
@article{1663c37f24814d3fa302d446eb129c6c,
title = "Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: Potential therapeutic significance",
abstract = "BACKGROUND. The malignant Hodgkin and Reed-Sternberg (H/RS) cells of Hodgkin disease (HD) express CD30 and CD40 receptors that can activate nuclear factor kappa B and transduce survival signals. The authors have reported previously that the B lymphocytes of HD express CD30 ligand (CD30L, CD153). Furthermore, they and others have reported previously that the CD40L survival pathway is augmented in patients with B-cell malignancies, as CD40L was constitutively expressed by the malignant B cells and infiltrating T cells, and sera from those patients contained elevated levels of soluble CD40L. In this study, the authors investigated the hypothesis that the survival of H/RS cells was similarly promoted by an augmented CD40L signals in HD patients. METHODS. The expression of CD40L on lymphocyte subsets of patients with classic HD was determined by two-color fluorescent-activated cell sorter analysis. Serum soluble CD40L levels were determined by enzyme linked immunosorbent assay. RESULTS. CD40L was constitutively expressed on both the T and B cells of HD patients but was more prominently expressed on the B lymphocytes. Soluble CD40L was detected in the serum of 17 of 37 patients (45{\%}) and was higher than 1 ng/mL in 4 patients (10{\%}). Both interleukin (IL)-4 and IL-10, which are known to be secreted by H/RS cells and surrounding T cells, up-regulated CD40L expression on normal B cells. CONCLUSIONS. Thus, the expression of CD40L and CD30L on the B cells of HD patients suggests that B lymphocytes may play a role in the regulation of H/RS cell growth in vivo. Depriving H/RS cells from CD30L and CD40L survival signals by eliminating B cells from HD lesions may be of therapeutic value.",
keywords = "B lymphocytes, CD154, CD40, Reed-Sternberg cells",
author = "Katharina Clodi and Zahra Asgari and Mamoun Younes and Palmer, {J. Lynn} and Fernando Cabanillas and Antonino Carbone and Michael Andreeff and Anas Younes",
year = "2002",
month = "1",
day = "1",
doi = "10.1002/cncr.10164",
language = "English",
volume = "94",
pages = "1--5",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease

T2 - Potential therapeutic significance

AU - Clodi, Katharina

AU - Asgari, Zahra

AU - Younes, Mamoun

AU - Palmer, J. Lynn

AU - Cabanillas, Fernando

AU - Carbone, Antonino

AU - Andreeff, Michael

AU - Younes, Anas

PY - 2002/1/1

Y1 - 2002/1/1

N2 - BACKGROUND. The malignant Hodgkin and Reed-Sternberg (H/RS) cells of Hodgkin disease (HD) express CD30 and CD40 receptors that can activate nuclear factor kappa B and transduce survival signals. The authors have reported previously that the B lymphocytes of HD express CD30 ligand (CD30L, CD153). Furthermore, they and others have reported previously that the CD40L survival pathway is augmented in patients with B-cell malignancies, as CD40L was constitutively expressed by the malignant B cells and infiltrating T cells, and sera from those patients contained elevated levels of soluble CD40L. In this study, the authors investigated the hypothesis that the survival of H/RS cells was similarly promoted by an augmented CD40L signals in HD patients. METHODS. The expression of CD40L on lymphocyte subsets of patients with classic HD was determined by two-color fluorescent-activated cell sorter analysis. Serum soluble CD40L levels were determined by enzyme linked immunosorbent assay. RESULTS. CD40L was constitutively expressed on both the T and B cells of HD patients but was more prominently expressed on the B lymphocytes. Soluble CD40L was detected in the serum of 17 of 37 patients (45%) and was higher than 1 ng/mL in 4 patients (10%). Both interleukin (IL)-4 and IL-10, which are known to be secreted by H/RS cells and surrounding T cells, up-regulated CD40L expression on normal B cells. CONCLUSIONS. Thus, the expression of CD40L and CD30L on the B cells of HD patients suggests that B lymphocytes may play a role in the regulation of H/RS cell growth in vivo. Depriving H/RS cells from CD30L and CD40L survival signals by eliminating B cells from HD lesions may be of therapeutic value.

AB - BACKGROUND. The malignant Hodgkin and Reed-Sternberg (H/RS) cells of Hodgkin disease (HD) express CD30 and CD40 receptors that can activate nuclear factor kappa B and transduce survival signals. The authors have reported previously that the B lymphocytes of HD express CD30 ligand (CD30L, CD153). Furthermore, they and others have reported previously that the CD40L survival pathway is augmented in patients with B-cell malignancies, as CD40L was constitutively expressed by the malignant B cells and infiltrating T cells, and sera from those patients contained elevated levels of soluble CD40L. In this study, the authors investigated the hypothesis that the survival of H/RS cells was similarly promoted by an augmented CD40L signals in HD patients. METHODS. The expression of CD40L on lymphocyte subsets of patients with classic HD was determined by two-color fluorescent-activated cell sorter analysis. Serum soluble CD40L levels were determined by enzyme linked immunosorbent assay. RESULTS. CD40L was constitutively expressed on both the T and B cells of HD patients but was more prominently expressed on the B lymphocytes. Soluble CD40L was detected in the serum of 17 of 37 patients (45%) and was higher than 1 ng/mL in 4 patients (10%). Both interleukin (IL)-4 and IL-10, which are known to be secreted by H/RS cells and surrounding T cells, up-regulated CD40L expression on normal B cells. CONCLUSIONS. Thus, the expression of CD40L and CD30L on the B cells of HD patients suggests that B lymphocytes may play a role in the regulation of H/RS cell growth in vivo. Depriving H/RS cells from CD30L and CD40L survival signals by eliminating B cells from HD lesions may be of therapeutic value.

KW - B lymphocytes

KW - CD154

KW - CD40

KW - Reed-Sternberg cells

UR - http://www.scopus.com/inward/record.url?scp=0036143638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036143638&partnerID=8YFLogxK

U2 - 10.1002/cncr.10164

DO - 10.1002/cncr.10164

M3 - Article

VL - 94

SP - 1

EP - 5

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -